Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab S/C in combination with cyclophosphamide, doxorubicin, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's Lymphoma.

This is written in the approval document as:

Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's lymphoma (NHL).

Citation

Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/dose-adjusted-rituximab-s-c-etoposide-prednisolone-doxorubicin-cyclophosphamide-and-vincristine-da-r-s-c-epoch-therapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
Sensitivity (+) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine